Compounds > n-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-n,n',n',n'',n''-pentaacetic acid
Page last updated: 2024-09-05

n-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-n,n',n',n'',n''-pentaacetic acid and Sensitivity and Specificity

n-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-n,n',n',n'',n''-pentaacetic acid has been researched along with Sensitivity and Specificity in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Brechbiel, MW; Chappell, LL; Dadachova, E; Garmestani, K; Ma, D; Milenic, DE; Schlom, J; Yordanov, A1

Other Studies

1 other study(ies) available for n-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-n,n',n',n'',n''-pentaacetic acid and Sensitivity and Specificity

ArticleYear
In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications.
    Nuclear medicine and biology, 2002, Volume: 29, Issue:4

    Topics: Adenocarcinoma; Aniline Compounds; Animals; Antibodies, Monoclonal; Colonic Neoplasms; Female; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Humans; Immunoconjugates; Isothiocyanates; Lutetium; Mice; Mice, Nude; Pentetic Acid; Radioimmunotherapy; Radiopharmaceuticals; Sensitivity and Specificity; Tissue Distribution; Whole-Body Counting; Xenograft Model Antitumor Assays

2002